Quantcast
Last updated on April 17, 2014 at 21:23 EDT

Latest antibodies Stories

2013-12-05 23:23:43

RnRMarketResearch.com adds “Biosimilars Market Product [Recombinant Non-Glycosylated Proteins (Insulin, Filgrastim, Somatropin), Glycosylated (Monoclonal Antibodies, Erythropoietin), Peptides (Glucagon, Calcitonin)] & Application (Oncology, Blood Disorders) – Global Forecast to 2018” to its store. Dallas, Texas (PRWEB) December 05, 2013 The biosimilar products market is segmented into recombinant non-glycosylated proteins, recombinant glycosylated proteins, and recombinant...

2013-12-05 16:25:31

- KB004, experimental anti-EphA3 monoclonal antibody therapeutic, in clinical development against hematologic cancers SOUTH SAN FRANCISCO, Calif., Dec. 5, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO), today announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a composition of matter patent covering certain antibodies targeting EphA3, including KaloBios' experimental anti-cancer monoclonal antibody (mAb), KB004. The allowed claims...

2013-12-03 08:33:10

Tolera seeking partner for lead Ph2/Ph3 asset for solid organ transplantation KALAMAZOO, Mich., Dec. 3, 2013 /PRNewswire/ -- Tolera Therapeutics, Inc., a privately-held, immune therapy company developing a novel T-cell targeted therapeutic platform, announced today that it has appointed Ashleigh Palmer as President, CEO and Board Director. Tolera's Chairman, Suzette Dutch, Managing Partner of Triathlon Medical Ventures, said, "Ashleigh has an ideal track record in developing,...

2013-12-03 08:31:26

Full article: http://bit.ly/EpiVax_Biotest DREIEICH, Germany and PROVIDENCE, R.I., Dec. 3, 2013 /PRNewswire/ -- Biotest AG, Dreieich, Germany and EpiVax, Inc., Providence, Rhode Island, USA are pleased to announce a new Collaborative Research Agreement. With this collaboration a novel, non-immunogenic Factor VIII (FVIII) should be developed. The coagulation factor VIII used for Hemophilia therapy will be altered in such a way that the immune system of the patients may not respond by...

Nanomedicine May One Day Be Delivered Orally
2013-11-28 04:43:35

redOrbit Staff & Wire Reports - Your Universe Online Researchers from MIT and Brigham and Women's Hospital (BWH) have developed a new type of nanoparticle that can be absorbed through the digestive tract, bringing the cutting-edge treatment method one-step closer to being administered orally instead of through injections. While drugs delivered by nanoparticles could help treat cancer, diabetes and several other types of disease, the fact that these particles currently have to be...

2013-11-27 12:24:07

DUBLIN, November 27, 2013 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/7lgrpn/flatrate) has announced the addition of the "Flat-Rate Subscription to La Merie Publishing Reports" [http://www.researchandmarkets.com/research/7lgrpn/flatrate ] to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) This subscription provides access during one year to all existing and new reports produced by La Merie Publishing...

Decoding An Individual's Immune System
2013-11-21 15:12:21

University of California - Santa Barbara You may be sensitive to gluten, but you're not sure. Perhaps you can't put your finger on a recurring malaise, and your doctor is at a loss to figure it out. A diagnostic method recently developed by UC Santa Barbara professor Patrick Daugherty can reveal — on a molecular level — the factors behind conditions thought to have environmental triggers. By decoding an individual's immune system, this elegant and accurate method can demystify,...

2013-11-12 23:27:58

Monoclonal antibodies specific to Rift Valley Fever Virus developed by Maine Biotechnology Services, in partnership with the USDA-Agricultural Research Service, are now available for sampling. The antibodies were developed to support ongoing research efforts to advance adequate vaccine and rapid detection methods. Portland, Maine (PRWEB) November 12, 2013 In July 2012, Maine Biotechnology Services entered into a partnership with Dr. Scott McVey, supervisor of the USDA-Agricultural...

2013-11-05 08:34:27

SAN DIEGO, Nov. 5, 2013 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) announced today that it has entered into an antibody and vaccine development collaboration with The Scripps Research Institute (TSRI) of La Jolla, CA. Under the terms of the agreement, Sorrento obtains an exclusive, worldwide license to TSRI's novel technologies based on ghrelin signaling inhibition for the prevention and treatment of obesity and other metabolic disorders. A research group...

2013-11-01 08:26:52

Novel hydrogel acts as drug delivery depot that reduces tumor size in fewer treatments than traditional therapies SAN JOSE, Calif., Nov. 1, 2013 /PRNewswire/ -- Today, scientists from IBM (NYSE: IBM) and Singapore's Institute of Bioengineering and Nanotechnology (IBN) published a breakthrough drug-delivery technique, demonstrating the first biodegradable, biocompatible and non-toxic hydrogel that can deliver treatment more efficiently to people fighting breast cancer. (Logo:...